Research progress on PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer / 中国胸心血管外科临床杂志
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
; (12): 953-959, 2020.
Article
in Zh
| WPRIM
| ID: wpr-824998
Responsible library:
WPRO
ABSTRACT
@#Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) signaling pathway has been found capable of affecting anti-tumor immune effect in many malignancies in recent years. Patients who are diagnosed with advanced non-small cell lung cancer (NSCLC) have considerable responses after receving inhibitors against PD-1/PD-L1. This paper reviews the clinical progress of PD-1/PD-L1 inhibitors in the treatment of NSCLC.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
Year:
2020
Type:
Article